IYXI Stock Overview
Through its wholly-owned subsidiaries, operates as a specialty pharmaceutical company in the United States, Canada, and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Inyx, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | -99.94% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| IYXI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 3.4% | 1.6% |
| 1Y | n/a | 14.2% | 32.3% |
Return vs Industry: Insufficient data to determine how IYXI performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how IYXI performed against the US Market.
Price Volatility
| IYXI volatility | |
|---|---|
| IYXI Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IYXI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine IYXI's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | n/a | n/a |
Inyx, Inc., through its wholly-owned subsidiaries, operates as a specialty pharmaceutical company in the United States, Canada, and Europe. It develops and manufactures prescription and over-the-counter pharmaceutical products. The company manufactures hydrocarbon aerosols, a delivery system for dermatological and topical drug applications; metered dose inhalers that are used for respiratory conditions; dry powdered inhalers used for respiratory ailments; metered dose nasal and throat pumps, and sprays; and sterile salines and injectables.
Inyx, Inc. Fundamentals Summary
| IYXI fundamental statistics | |
|---|---|
| Market cap | US$53.00 |
| Earnings (TTM) | -US$36.21m |
| Revenue (TTM) | US$85.04m |
0.0x
P/S Ratio0.0x
P/E RatioIs IYXI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IYXI income statement (TTM) | |
|---|---|
| Revenue | US$85.04m |
| Cost of Revenue | US$54.85m |
| Gross Profit | US$30.19m |
| Other Expenses | US$66.39m |
| Earnings | -US$36.21m |
Last Reported Earnings
Sep 30, 2006
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did IYXI perform over the long term?
See historical performance and comparison